FindTrial
Sign In

Mitomycin C (MMC)

DRUG6 trials

Sponsors

Shahid Beheshti University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Shaogang Wang, First Affiliated Hospital of Wenzhou Medical University

Conditions

Bladder CancerCarcinoma in Situ of BladderCarcinoma, Transitional CellNon-Muscle-Invasive Bladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)Peritoneal CarcinomatosisRefractory GlaucomaUrinary Bladder Neoplasms

Phase 1

Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma
NCT00893490
Shahid Beheshti University of Medical SciencesRefractory Glaucoma
Updated: 2009-05-06
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
Not yet recruitingNCT07487168
H. Lee Moffitt Cancer Center and Research InstitutePeritoneal Carcinomatosis
Start: 2026-03-01End: 2028-03-01Target: 24Updated: 2026-03-23

Phase 2

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Not yet recruitingNCT07189793
First Affiliated Hospital of Wenzhou Medical UniversityCarcinoma in Situ of Bladder, Carcinoma, Transitional Cell, Non-Muscle-Invasive Bladder Cancer +1
Start: 2025-10-31End: 2028-10-31Target: 106Updated: 2025-09-24

Phase 3

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
TerminatedNCT00974818
Memorial Sloan Kettering Cancer CenterBladder Cancer
Start: 2009-09-30End: 2012-03-31Updated: 2015-11-20
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Active, not recruitingNCT04241185
Merck Sharp & Dohme LLCUrinary Bladder Neoplasms
Start: 2020-05-19End: 2031-11-01Target: 520Updated: 2024-11-25
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
RecruitingNCT06696794
Shaogang WangNon-Muscle-Invasive Bladder Cancer (NMIBC)
Start: 2025-02-17End: 2031-06-30Target: 180Updated: 2025-02-19

Related Papers

Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
Journal of Clinical Oncology2024-01-2910 citations
Abstract CT564: KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent chemoradiotherapy
Cancer Research2022-06-153 citations
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
Journal of Clinical Oncology2021-02-201 citations
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.
Journal of Clinical Oncology2020-05-2014 citations